bioMérieux announced the CE marking of BIOFIRE® Respiratory Panel 2.1 plus (RP2.1plus) tests for detection of 23 pathogens, including SARS-CoV-2.
Asia
Europe, Middle East, Africa
North America
bioMérieux 2019 Annual Report
13 July, 2020
In guiding the Company’s development, bioMérieux has always focused on meeting healthcare challenges related to infectious diseases all over the world. With over 90% of sales outside of France today, the scope of our activity is geographically balanced.
bioMérieux – Second-Quarter 2020 Business Performance Preannoucement
09 July, 2020
Marcy l'Étoile (France), July 9, 2020 – In light of the withdrawal of its annual objectives, bioMérieux, a world leader in the field of in vitro diagnostics, today announced preliminary quarterly information about its business activity ending June 30, 2020.
bioMérieux receives FDA clearance to extend platelet shelf life to 7 days with Large Volume Delayed Sampling strategy using BACT/ALERT® 3D and BACT/ALERT® VIRTUO® culture systems.
22 May, 2020
bioMérieux announces that its BACT/ALERT® BPA and BPN culture bottles have received 510(k) clearance from the U.S. Food and Drug Administration (FDA) for Large Volume Delayed Sampling (LVDS) of leukocyte-reduced apheresis platelets (LRAP) and leukocyte-reduced whole blood platelet concentrates (LRWBPC) with BACT/ALERT®3D and BACT/ALERT® VIRTUO® systems.
CE marking of bioMérieux serology tests for SARS-CoV-2 on VIDAS®
21 May, 2020
bioMérieux announced the CE marking of VIDAS anti-SARS-CoV-2 serology tests to detect antibodies in people who have been exposed to SARS-CoV-2 which causes the COVID-19 disease.
Memorial Day Shipping Schedule
12 May, 2020
Please be advised that major delivery services in the U.S. will be closed on Monday, May 25, 2020 in observance of the Memorial Day holiday. We encourage you to place orders with the following dates in mind.
bioMérieux serology tests for SARS-CoV-2 on VIDAS® undergo validation preceding imminent launch
06 May, 2020
bioMérieux announces the upcoming launch of VIDAS® anti-SARS-CoV-2 serology tests to detect antibodies in people who have been exposed to the SARS-CoV-2, complementing its existing COVID-19 solutions.
BIOFIRE® Respiratory Panel 2.1 (RP2.1) with SARS-CoV-2 obtains FDA Emergency Use Authorization
04 May, 2020
BioFire Diagnostics, a bioMérieux subsidiary, has received Emergency Use Authorization by the U.S. Food and Drug Administration of its BIOFIRE® RP2.1 panel, which includes 22 pathogens that cause respiratory infections, including SARS-CoV-2 (the cause of COVID-19 disease).
bioMérieux – First-Quarter 2020 Business Review
16 April, 2020
Marcy l'Étoile (France), April 16, 2020 – bioMérieux, a world leader in the field of in vitro diagnostics, released its business review for the three months ended March 31, 2020.
bioMérieux receives Emergency Use Authorization for BIOFIRE® COVID-19 test
24 March, 2020
BioFire Defense, a bioMérieux subsidiary, has received Emergency Use Authorization by the U.S. Food and Drug Administration of its BIOFIRE® COVID-19 test for use in CLIA moderate and high complexity clinical laboratories to detect SARS-CoV-2.